SDI Reports: 150 Pharmaceutical Brands New to ePromotion in 2010

Prolia Leads ePromotion Activities Among New Entrants

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- SDI reports that more than 150 drugs were marketed using online details and events for the first time in 2010. Amgen’s Prolia led the new entrants with over 7,600 online promotional activities during the first 9 months of the year. Merck’s Dulera and Vimovo, co-developed by POZEN and AstraZeneca, were second and third with approximately 6,100 and 4,100 activities, respectively.

Industrywide, over 3.4 million ePromotion activities took place and $396 million was spent on this type of promotion during the first 9 months of 2010.

Merck’s Singulair led the industry in ePromotion with over 110,000 activities in the first 9 months of 2010. Pfizer’s Pristiq and Merck’s Januvia were second and third with almost 104,000 and 89,000 activities, respectively.

“The pharmaceutical industry’s investment in ePromotion has dramatically increased in recent years,” said Christa Wagner, Product Manager, SDI. “From 2005 to 2009, ePromotion spending increased 86%. Based on activity so far this year, we expect spending in 2010 to exceed last year’s.”

About SDI

SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, retail pharmacy, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world’s top 50 pharmaceutical and biotech firms as its clients.



CONTACT:

SDI
Scott Evans, 484-567-6353
[email protected]
or
Buchanan Public Relations
Jack Loughran, 610-649-9292
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Communications  Marketing

MEDIA:

Logo
 Logo

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.